Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors ( sor genes thereby promoting tumor grow...)

Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

sor genes, thereby promoting tumor growth. MGCD0103 is an orally-administered, selective HDAC inhibitor, which targets specific class I HDAC isotypes. Preclinical data suggest that these HDAC isotypes are important in cancer biology and, consequently, such selective HDAC inhibitors may have increased efficacy and reduced toxicity compared to non-selective inhibitors.

Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (Trial 005)

Data presented in a poster session by Guillermo Garcia-Manero, M.D., principal investigator, Associate Professor of Medicine and Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, M.D. Anderson Cancer Centre, demonstrated that combination treatment with MGCD0103 and Vidaza(r) (azacitidine for injection) resulted in a 30 percent response rate for all patients, and a 37 percent response rate in the active dose ranges previously reported. Of the 37 patients in this trial, eleven patients (two MDS patients and nine AML patients) experienced objective clinical responses. In addition, the combination therapy showed good pharmacodynamic properties and acceptable safety in these patients.

"MGCD0103 and Vidaza are two epigenetic agents that have demonstrated single-agent activity in AML and MDS," said Dr. Garcia-Manero. "In this study we found that these agents can be given together, and that the resulting clinical activity is better than expected from each agent alone."

"We are very encouraged by the single-agent activity to date in our Hodgkin's lymphoma trial. These patients have progressive disease after receiving multiple prior therapies and there are currently no approved alternative treatments available to them," said Donald F. Corcoran, President and Chief Executive Officer of MethylGene. "In addition, the responses in our Vidaza-MGCD0103 combination trial are consistent with our earlier data. The data from these two ongoing trials have given us potential direction for registratio
'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

Post Your Comments:

(Date:12/15/2009)... NASHVILLE, Tenn., Dec. 15 Cumberland ... announced new top-line results for a ... for Oral Solution, a prescription laxative packaged as ... liquid forms. ,, Kristalose is the only prescription-strength ... 14-day period, 50 patients with a recent diagnosis ...

(Date:12/15/2009)... Dec. 15 Dynatronics Corporation ... a preferred vendor agreement to provide therapy equipment ... (PTP), a nationwide network of physical, occupational and ... working with Preferred Therapy Providers," said Larry K. ... at Dynatronics. "Their vast network of 1,100 clinics ...

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... of the competitive environment is unquestionably ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...

Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3 Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2 Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2 Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 1 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 2 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 3 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 4 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 5 Dallas Physician Elected to Lead International Organ Transplant Society 55053 1 Dallas Physician Elected to Lead International Organ Transplant Society 55053 2 Dallas Physician Elected to Lead International Organ Transplant Society 55053 3 Gene Linked to Inherited Kidney Disease Found 55049 1

[0] Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study [0] Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.[0] Reportlinker Adds Top Ten World's Leading Orthopedics Companies

... PARIS, June 30 Five years after the ... disease causing accelerated and,premature ageing, a team of ... University of Oviedo - and Nicolas Levy and ... treatment,for the disease, using mice. This treatment, combining ...

... LONDON and PHILADELPHIA, June 30 ,GlaxoSmithKline (NYSE: GSK ... the U.S. Food and Drug Administration (FDA) for approval,of ... has submitted its response to questions raised by the ... In addition, given,that final data from GSK,s Phase III ...

Other Medicine Technology:Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2 GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 2 GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 3

Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval

(Date:12/15/2009)... BALTIMORE, Dec. 15 SUMMARY: ... the Patient Protection and Affordable Care Act that ... by allowing for the safe and legal importation ... amendment, endorsed by AARP and sponsored by Senators ... improved competition and helped to bring down the ...

(Date:12/15/2009)... of coal for lying about taxes in the healthcare bill ... Baucus has earned a place under the "Naughty" column on ... after being caught telling a brazen lie on the ... healthcare bill would not raise taxes. ,, Speaking on ... " I have also heard ...

(Date:12/15/2009)... of leptin associated with lower dementia risk, research finds ... levels of leptin, a hormone that regulates appetite, may ... in 10 or 15 years this may be one ... risk of Alzheimer,s disease," said senior study author Dr. ... University School of Medicine. "Or it may be one ...

(Date:12/15/2009)... education program will train advocates to be leaders ... Project developed with support from experts in online ... ,, WASHINGTON, Dec. 15 ... are accepting applications for the first-ever "Malaria Griots" ... and educate participants to become leaders in the ...

(Date:12/15/2009)... The following are the remarks by ... criminal division, at the Medicare Fraud Strike Force ... thank you for the enormous effort everyone at ... ,, Together, our Departments have and will continue ... made tremendous progress in fighting Medicare fraud in ...

Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2 Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3 Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 2 Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 3 Health News:Fat Hormone May Protect Against Alzheimer's 2 Health News:Fat Hormone May Protect Against Alzheimer's 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 2 Health News:ONE and Malaria No More Launch 'Malaria Griots' 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 4 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3

[0] AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices [0] ATR: Baucus Earns Place on 2009 "Naughty" List [0] Fat Hormone May Protect Against Alzheimer's [0] ONE and Malaria No More Launch 'Malaria Griots'[1] Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference

... (Washington) "The benefits of widespread adoption of interoperable ... to a higher standard of quality in the U.S. ... House Ways and Means Committee subcommittee on Health today. ... their patients will be left behind the technological curve." ...

... Immunochemist Mark C. Swanson got,leading scientists and ... a bright future for natural rubber latex (NRL) ... of Vytex(TM),NRL from Vystar Corporation. This commercially available ... as raw material while,preserving desirable NRL properties in ...

... research facility is planned to enable unprecedented understanding of ... human behaviour. The 28.5 million funding comes from ... and Skills (DIUS), and will be used for the ... a collaboration between the Economic and Social Research Council ...

... annual Retail Business Conference, company launches exclusive brand, ... outbound ... technology, ORLANDO, Fla., July 24 As consumerism, ... the way health care is delivered, Cardinal Health today ...

... The board of,directors for Hillenbrand, Inc. (NYSE: ... million of the company,s outstanding common shares. Purchases,will be ... or in privately,negotiated transactions, and will be funded from ... decision to implement a share repurchase program for our,new ...

... $0.38 in ... Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding $0.05 in ... from the 2003 spin-off ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

ACP says Medicare should increase payments for physicians that use HIT to improve quality Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing £28.5M investment for groundbreaking new research facility Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance

... improved OrthoWedge® Healing Shoe offers the most ... forefoot while allowing patients to maintain their ... wedge, an even larger portion of the ... the metatarsal heads and toes to heal ...

Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....

... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...

... is a given with our High Beam TriLens ... and remarkably brilliant 11.5 cm spot at a ... its class. , ,To achieve this unequaled performance ... with three of the finest Mag-Fluoride coated lenses ...

Medicine Products:

OrthoWedge Healing Shoes Polycast Cast Boot Gliadin IgG Kit High Beam TriLens Classic and Sport

( sor genes thereby promoting tumor grow...)Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors,Health